2 startups win big at Accenture's ​Houston-based health tech competition

winner, winner

For the first time, Accenture hosted its HealthTech Innovation Challenge finals at the Texas Medical Center's Innovation Institute. Photo courtesy of Accenture

Two health tech companies walked away from Accenture's HealthTech Innovation Challenge with awards. Regionals took place in Boston and San Francisco, and Houston was selected to host the finals last week.

New York-based Capital Rx was selected as the 2020 Innovation Champion of the Accenture HealthTech Innovation Challenge, and Minneapolis-based Carrot Health was given the second-place award for Top Innovator. The program, which was first launched in 2016, aims to pair startups with health organizations to drive innovative solutions to real challenges in health care.

"The submissions we received this year demonstrate the momentum of discovery and digital innovation in healthcare," says Brian Kalis, managing director of digital health and innovation at Accenture, in a news release. "Healthcare organizations continue to advance their digital transformation agendas — enhancing access, affordability, quality and experience to drive innovation that improves the lives of consumers and clinicians. We look forward to working with these companies and others to continue to help advance solutions that address the industry's toughest challenges."

Capital Rx, a pharmacy benefit manager, won for its product, the Clearinghouse ModelSM, which connects pharmacies and employers for a more efficient and transparent way to coordinate prescriptions.

"Receiving the designation as Innovation Champion is a validation of our mission to change the way drugs are priced and administered, and it represents the broad support across the country to transform the antiquated and opaque pricing model for prescription drugs," says AJ Loiacono, CEO of Capital Rx, in the release.

Carrot Health, which took second place, has created algorithms to use consumer data analytics to predict and determine health issues. Its MarketView platform weighs in factors including social, economic, behavior, and environmental information.

"It's been a great opportunity to be with Accenture and a broad spectrum of health care players," says Kurt Waltenbaugh, CEO and founder of Carrot Health, in the release. "Being recognized as the Top Innovator will help us expand our footprint toward our goal to change health and serve every person in the U.S."

A total of 11 finalists pitched in Houston at TMCx on Feb, 6. The other finalists included: San Francisco-based Cleo, Boston-based DynamiCare Health, San Francisco-based InsightRX, United Kingdom-based Lantum, Washington, D.C.-based Mira, Denver-based Orderly Health, New York City-based Paloma Health, St. Louis-based TCARE, and Seattle-based Xealth.

It was the first time the challenge was hosted at the Texas Medical Center, and William F. McKeon, TMC president and CEO, took the stage at the event to share the medical city's vision for the future.

"The opportunity to host the HealthTech Innovation Challenge in Houston for the first time re-enforces our city's prominent and ever-expanding designation as a major hub for healthcare innovation nationwide," McKeon says in the release. "As Texas Medical Center heads into a new era of collaborative healthcare research on our forthcoming TMC3 campus, we look forward to maintaining a fruitful long-term partnership with Accenture."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

Houston company plans lunar mission to test clean energy resource

lunar power

Houston-based natural resource and lunar development company Black Moon Energy Corporation (BMEC) announced that it is planning a robotic mission to the surface of the moon within the next five years.

The company has engaged NASA’s Jet Propulsion Laboratory (JPL) and Caltech to carry out the mission’s robotic systems, scientific instrumentation, data acquisition and mission operations. Black Moon will lead mission management, resource-assessment strategy and large-scale operations planning.

The goal of the year-long expedition will be to gather data and perform operations to determine the feasibility of a lunar Helium-3 supply chain. Helium-3 is abundant on the surface of the moon, but extremely rare on Earth. BMEC believes it could be a solution to the world's accelerating energy challenges.

Helium-3 fusion releases 4 million times more energy than the combustion of fossil fuels and four times more energy than traditional nuclear fission in a “clean” manner with no primary radioactive products or environmental issues, according to BMEC. Additionally, the company estimates that there is enough lunar Helium-3 to power humanity for thousands of years.

"By combining Black Moon's expertise in resource development with JPL and Caltech's renowned scientific and engineering capabilities, we are building the knowledge base required to power a new era of clean, abundant, and affordable energy for the entire planet," David Warden, CEO of BMEC, said in a news release.

The company says that information gathered from the planned lunar mission will support potential applications in fusion power generation, national security systems, quantum computing, radiation detection, medical imaging and cryogenic technologies.

Black Moon Energy was founded in 2022 by David Warden, Leroy Chiao, Peter Jones and Dan Warden. Chiao served as a NASA astronaut for 15 years. The other founders have held positions at Rice University, Schlumberger, BP and other major energy space organizations.

Houston co. makes breakthrough in clean carbon fiber manufacturing

Future of Fiber

Houston-based Mars Materials has made a breakthrough in turning stored carbon dioxide into everyday products.

In partnership with the Textile Innovation Engine of North Carolina and North Carolina State University, Mars Materials turned its CO2-derived product into a high-quality raw material for producing carbon fiber, according to a news release. According to the company, the product works "exactly like" the traditional chemical used to create carbon fiber that is derived from oil and coal.

Testing showed the end product met the high standards required for high-performance carbon fiber. Carbon fiber finds its way into aircraft, missile components, drones, racecars, golf clubs, snowboards, bridges, X-ray equipment, prosthetics, wind turbine blades and more.

The successful test “keeps a promise we made to our investors and the industry,” Aaron Fitzgerald, co-founder and CEO of Mars Materials, said in the release. “We proved we can make carbon fiber from the air without losing any quality.”

“Just as we did with our water-soluble polymers, getting it right on the first try allows us to move faster,” Fitzgerald adds. “We can now focus on scaling up production to accelerate bringing manufacturing of this critical material back to the U.S.”

Mars Materials, founded in 2019, converts captured carbon into resources, such as carbon fiber and wastewater treatment chemicals. Investors include Untapped Capital, Prithvi Ventures, Climate Capital Collective, Overlap Holdings, BlackTech Capital, Jonathan Azoff, Nate Salpeter and Brian Andrés Helmick.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings